Market closedADR

Burning Rock Biotech/$BNR

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Burning Rock Biotech

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Ticker

$BNR
Trading on

Industry

Biotechnology
Headquarters

Employees

786

BNR Metrics

BasicAdvanced
$68M
Market cap
-
P/E ratio
-$5.71
EPS
0.60
Beta
-
Dividend rate
$68M
0.6
$9.99
$2.62
17K
3.037
2.639
11.271
15.567
-25.68%
-56.59%
0.965
0.1
0.1
-3.606
-8.54%
-39.77%
1.25%
-14.84%

What the Analysts think about BNR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Burning Rock Biotech stock.

BNR Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BNR Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BNR

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Burning Rock Biotech stock?

Burning Rock Biotech (BNR) has a market cap of $68M as of December 22, 2024.

What is the P/E ratio for Burning Rock Biotech stock?

The price to earnings (P/E) ratio for Burning Rock Biotech (BNR) stock is 0 as of December 22, 2024.

Does Burning Rock Biotech stock pay dividends?

No, Burning Rock Biotech (BNR) stock does not pay dividends to its shareholders as of December 22, 2024.

When is the next Burning Rock Biotech dividend payment date?

Burning Rock Biotech (BNR) stock does not pay dividends to its shareholders.

What is the beta indicator for Burning Rock Biotech?

Burning Rock Biotech (BNR) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.